article
How GPCR agonists, including antibodies, are shaping the future of metabolic care
Find out how Confo Therapeutics is overcoming challenges in GPCR drug development to create next-gen therapies for metabolic diseases.
List view / Grid view
GPCRs
news
AI for drug discovery in advanced pain management
A deep-learning model found metabolites and drugs that could be repurposed for non-addictive and non-opioid options to treat chronic pain.
webinar
The value of GPCR cell-based assays in drug discovery
20 June 2024 | By Eurofins DiscoverX
Join this webinar to discover how GPCR functional, cell-based assays determine off-target effects, reveal safety issues, and define drug mechanism of action to ultimately evaluate the therapeutic potential of candidate molecules.
article
Advancing directed protein evolution technology
Drug Target Review's Ria Kakkad spoke with Victoria Goldenshtein at PEGs Europe, about her lab’s novel in vitro library display platform for directed protein evolution called GRIP display – gluing RNA to its proteins.
news
New method of designing drugs without side effects
Japanese researchers now reveal a new way of activating GPCR by triggering shape changes in the intracellular region of the receptor. This new process can help researchers design drugs with fewer or no side effects.
webinar
Using integrative biophysical approaches to understand GPCR regulation by β-arrestins
30 January 2023 | By Thermo Fisher Scientific
Watch this webinar to learn how an integrated structural biology workflow can be used to get crucial structural insights on key protein targets that are of therapeutic interest.
news
Newly discovered GPCR signalling process opens possibility for novel therapies
US researchers have found that G protein-coupled receptors function in a way not previously known, which suggests untapped potential.
article
Insights into GPCRs via innovative imaging
In this exclusive Q&A, Drug Target Review’s Ria Kakkad spoke with Dr Jonathan Javitch, Professor at Columbia University’s Vagelos College of Physicians and Surgeons, about the cutting-edge imaging method single-molecule fluorescence resonance energy transfer (smFRET), used to investigate G protein-coupled receptors (GPCRs).
article
Antibody pipelines – the pharma perspective
Dr Erik Vernet, Director of Antibody Technology at Novo Nordisk, discusses antibody discovery and development workflows, including the role of informatics processes, in this Q&A.
news
Novel screening method identifies lead molecule for GPCR dimerisation
The new high-throughput screening method identified nine lead molecules for rhodopsin dimerisation that may lead to next-generation medicines.
news
Groundbreaking data tool may uncover novel class of GPCRs
A new computer-aided tool maps allosteric sites in G protein-coupled receptors to search for allosteric drugs to treat a range of diseases.
whitepaper
Flyer: Introducing Eurofins Beacon Discovery; the GPCR experts
Learn how you can partner for success with Eurofins Beacon Discovery’s industry leading GPCR experts to support your program from concept to clinic.
webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
news
Anti-C5aR antibody shows promise as immuno-oncology treatment
Pre-clinical studies have shown that the TJ210/MOR210 monoclonal antibody is successful at targeting tumours.
article
Could GPCRs be causing people to respond differently to the same drug?
Hannah Balfour explores how genetic variation in G-protein-coupled receptors (GPCRs) and the proteins that regulate the duration of G protein signalling could be contributing to disease and people’s divergent responses to the same therapeutics.